Recent studies which suggest the existence of an endogenous neural substrate of pain inhibition are reviewed. Electrical stimulation of some areas of the medial brain stem in laboratory rats has produced a dramatic degree of analgesia. Such stimulation-produced analgesia is partially blocked by an opiate antagonist drug. This observation has proved seminal to those searching for endogenous opiate-like neurochemicals, the opioid peptides (enkephalins and endorphins). Particular attention is focused on studies of stimulation-produced analgesia, the underlying anatomy and physiology of endogenous analgesia systems elucidated by such work, and the relation of these findings to discoveries about opiate receptors and opioid peptides. Very recent work suggesting that certain forms of stress are natural triggers for activating endogenous analgesia mechanisms is described. Although certain stressors cause analgesia mediated by opioids, other stressors cause analgesia by neurochemically different means. Thus, mUltiple analgesia substrates, opioid and nonopioid, appear to exist.
and improve patient care. One such development that has both markedly altered our basic understanding of pain mechanisms and also led to a new pain treatment approach has been the discovery of a central nervous system substrate whose normal function appears to be the blocking of pain. This substrate includes portions of the medial brain stem, descending pathways, and target zones in the spinal cord dorsal horn and appears to use opioid peptides (enkephalins and endorphins) as chemical mediators.4-6 Discovery of this substrate derived from animal experimentation showing that direct electrical stimulation of the medial brain stem of the awake raC,8 and cae caused powerful pain inhibition, including the blocking of spinal nociceptive reflexes 8 and nociceptive responding of spinal neurons. 9 Such stimulation-produced analgesia (SPA) has now been demonstrated in man,IO·12 and the weight. of the early evidence suggests that this technique will remain a useful addition to the arsenal of pain therapies (see, however I3 ). The most useful clinical benefits of Ihese new discoveries, however, have probably yet to be achieved and will appear only when noninvasive means are found to control activation of the brain's own endogenous analgesic properties. The purpose of this article is to review briefly some of the major empirical findings and theoretical concepts in this very new but already extensive field of investigation.
Electrically stimulating the periaqueductal gray matter, a medial midbrain struct ure of the brain stem, evokes dramatic analgesia in rats, cats and monkeys across a wide variety of analgesiometric test conditions. 46 The potency of this SPA is comparable to that achieved by high doses of narcotic analgesic drugs such as morphine. 7 Medial, caudal regions of the diencephalon are also effective SPA sites in animals;14 and one of these, the periventricular gray matter, appears to be the most useful target in clinical trials because aversive side effects that sometimes accompany periaqueductal stimulation are seen less often here. II ,12 Medial portions of the lower brain stem, including especially the nucleus raphe magnus of the rostral medulla, are not only SPA sites but also relay stations between more rostral SPA areas and the apparent ultimate sites of pain inhibition in the spinal cord. ls Some basic features of SPA are the following:
1. That in a given animal the analgesic effect may be seen in one body region, but at the same time not elsewhere. 7 ,s It seems brain stimulation does not render the animal incapable of responding to pain since it can respond normally if the noxious stimulus is applied outside the peripheral analgesic field. Pain itself is affected by SPA, not the animal's ability to show that it hurts. 2. That analgesia can outlast the required brief period (several seconds) of brain stimulation, sometimes by many minutes or even a few hours. 7 ,s In man, brief selfapplied stimulation can afford many hours of relief from chronic pain symptoms. 12 3. That for certain electrode placements a rat will self-administer brain stimulation only when in pain. s Since brain stimulation is not itself rewarding in such a case but only becomes reinforcing in the presence of pain, its reinforcing value must derive from pain reduction rather than pleasure induction. 4. Other deficits and behavioural alterations do not regularly accompany pain inhibition with SPA. 7 ,8 The effect, therefore, may be considered specifically antinociceptive and not secondary to any other stimulationproduced change.
It first became apparent that SPA had an ultimate spinal site of action when we observed that spinally mediated pain reflexes could be completely inhibited by brain stem stimulation. 8 It was also known at that time that at least part of morphine's analgesic effect was suppressed by spinal transection. 16 Whatever direct effect opiates have on the spinal cord,17 it seems they also activate a descending pathway from the brain to the spinal cord, perhaps the same one activated by SPA. It now seems clear that medial brain stem stimulation inhibits transmission of pain messages through spinal neurons whose axons project to the brain. Both the specifically nociceptive neurons of the dorsal horn and those not specifically, but differentially responsive to pain are seen to be under an important degree of descending control. 4 ,9 Because the output of these neurons is the brain's major source of nociceptive information, the fact that they are under centrifugal control means the pain can regulate its own pain input. The theoretical implications of this fact and its potential utility in the domain of pain management are of great and obvious importance.
A particular heuristic theme to have come out of the SPA literat ure is the one suggesting t hat SPA shares a number of important features with opiate analgesiaY Many of the same brain areas supporting SPA also support analgesia when microinjections of opiate drugs are made at these sites. 17 ,18 Opiate binding sites (receptors) and opioid peptides are found in brain regions where SPA and opiate drugs appear best to work. 4 ,17,18 These peptides and their receptors, therefore, are well situated to function in a natural pain inhibitory system. In fact, evidence is available that opioids are released by analgesic brain stimulation. 19, 20 Perhaps the most salient finding in this regard was the one showing that the opiate antagonist, naloxone, could at least partly block SPA. 21, 22 This observation supported the view that SPA and opiate drugs share a common mechanism of action, a common neurochemistry. In conceptually related work, it was also found that tolerance develops to repeated SPA trials, as well as cross-tolerance between SPA and morphine analgesia. 23 Again, it was suggested that SPA and morphine exert their analgesic effects via a common receptor site, presumably the opiate receptor. Several more recent reports, however, have failed to demonstrate naloxone blockade of SPA. 24 We have now found that two different SPA areas exist in close proximity to one another within the periaqueductal gray matter. 25 ,26 Naloxone reliably antagonises SPA from the more ventral region without altering this effect elicited more dorsally. This finding may not resolve all aspects of the controversy, but it does appear to be an important beginning step.
Another important theoretical point is the supposition that the substrate we label an analgesia system is activated by various analgesic manipulations. The rationale is that something "turned on" by a manipulation that results in analgesia can be called a pain inhibitory system. We have performed a series of studies that appear to provide direct evidence for this activating effect. Our preparation has involved "multiple unit activity" (MUA) recording in the awake rat. We have found that both SP A27 and analgesic doses of morphine 28 ,29 augment baseline MUA in the periaqueductal gray matter and other portions of the medial brain stem that support SPA. In brain areas that do not support SPA, MUA is unaffected or may actually diminish. Naloxone blocks the MUA-activating effect of morphine;29 also, with repeated injections of morphine, tolerance develops to both the drug's analgesic and MUA-activating effect in a temporally correlated fashion. 28 In one study we showed that intraventricularly administered en kephalin caused analgesia in only half the animals investigated. However, it was only in those rats manifesting the analgesic effect that a corresponding rise in MUA from the periaqueductal gray matter was also observed. 3D Although several studies using the microelectrode technique have made rather opposite findings (showing that in the majority, the activity of individual neurons is depressed Anaesthesia and Infensive Care, Vol. X, No. 2, May, 1982 by opiate administration), such studies have generally been performed under surgical anaesthesia. We find that morphine reliably activates MUA in awake rats but has no effect or depresses this activity in urethane anaesthetised animals. 3 ! Again, this finding may not resolve all aspects of the disparity among these studies; but the burden of proof would seem to be on those using the abnormal conditions of general anaesthesia to study the neural mechanisms underlying opiate analgesia.
Certainly the most important question to ask of a putative endogenous analgesia system is, "what are the normal physiological triggers that activate it?" That is, to accept the existence of such a system we must know something about when it is used. One might suppose that an endogenous analgesia substrate would not be readily accessed or trivially employed; noxious stimuli are generally perceived as hurtful, and the warning signals they provide lead to important adaptive responses. On the other hand, perhaps under special emergency conditions when feeling pain could disrupt effective coping, pain suppression would have survival value. The recent literature on the analgesic effect of certain stressors lends credence to this view. It seems that stress may be one natural input to the endogenous analgesia system. Until recently, however, whether stress-induced analgesia was or was not mediated by opioid peptides remained in doubt. We have found that two different kinds of footshock stress, differing from each other only in their temporal parameters, caused equivalent analgesia, but the analgesia to one of these forms of footshock stress was blocked by naloxone, whereas that to the other form was not. 32 Analgesia from 20 minutes of intermittent footshock was naloxone sensitive, but analgesia from 3 minutes of continuous footshock of the same intensity was unaffected by this drug. We also found that the naloxone sensitive form of stress analgesia, but not the naloxone insensitive form, manifested tolerance with repeated stress trials as well as cross-tolerance with morphine. 33 It appears that opioid and nonopioid mechanisms of stress analgesia exist just as opioid and nonopioid forms of SPA were found to occur within the periaqueductal gray matter. So far, very little is known about the nonopioid type of analgesia. Hypophysectomy or adrenalectomy reduce opioid but not nonopioid stress analgesia,34 as does scopolamine, but not the centrally inactive methylscopolamine (J. Lewis, unpublished observation). It is essential to determine what transmitters or hormones underlie the nonopioid analgesia system. Because this system does not manifest tolerance and its activation ought not to be accompanied by other undesirable opiate effects, coming to understand its mechanisms of action could have important clinical implications.
It is becoming ever more clear that pain is not so focally represented in the nervous system, certainly not in the brain, as to permit its surgical excision. Ablative approaches to pain remain controversial, and the risk of iatrogenic pain resulting from pain surgery remains high. The very existence of pain inhibitory circuits in the brain and spinal cord, interruption of which would be expected to cause or exacerbate pain, gives us possible new grounds for understanding certain pain states caused by central nervous system lesions, whether these lesions are of pathological or surgical origin. Behavioural research is beginning to disclose reliable methods employing experiential manipulations and cognitive or conditioning techniques to trigger the endogenous analgesia system.6.35.37 These findings encourage the belief that these and similarly benign approaches to activating pain inhibitory systems can be perfected. Such strategies represent our best hope for major advances in pain therapy in the years to come.
